Clinical Trials Logo

Clinical Trial Summary

The overall purpose of this research is to develop and use a blood test to better understand how quickly the viral drug ganciclovir works to clear infection with the CMV virus (Cytomegalovirus) when it occurs. This test will potentially let doctors know early in the course of therapy when a virus is not responding well to the therapy and could therefore be resistant to the drug. The target population of this study will be primarily kidney and lung transplant patients with CMV detected in the blood, although other patients may also be included if they meet criteria. The study will be divided into two phases. Phase I will evaluate a small number of exploratory patients initiating ganciclovir therapy and will require frequent blood sampling to obtain detailed information regarding the kinetic response of the virus to therapy. This information will be analyzed to help guide decisions regarding the number and frequency of blood samples needed in the larger phase II portion of the study. Strains will be characterized using phenotypic and genotypic methods to determine the presence or absence of mutations potentially responsible for the resistance.

Clinical Trial Description


Study Design

Primary Purpose: Diagnostic

Related Conditions & MeSH terms

NCT number NCT00004573
Study type Interventional
Source National Center for Research Resources (NCRR)
Status Active, not recruiting
Phase N/A

See also
  Status Clinical Trial Phase
Recruiting NCT02671318 - Conversion to Sirolimus: Effects in Cytomegalovirus Infection Recurrence Phase 4
Completed NCT01325636 - Injection of CD4 and CD8 + T Cells Anti-Cytomegalovirus (CMV) or Anti-adenovirus Phase 1/Phase 2
Recruiting NCT00228202 - Genotyping of Cytomegalovirus From Patients in Israel N/A
Completed NCT00031421 - Neonatal CMV-Ganciclovir Follow-up Study N/A
Completed NCT00005496 - Inflammation, Infection, and Future Cardiovascular Risk N/A
Recruiting NCT03262194 - Relevance of Gastric Aspirate in HCMV Detection
Recruiting NCT02943057 - Topical 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis Phase 4
Recruiting NCT02538172 - Cell-mediated Immunity for Prevention of CMV Disease N/A
Completed NCT02642822 - The Epidemiologic Study of Human Cytomegalovirus(CMV) in Female Students of Xiamen University N/A
Completed NCT00673868 - Cytomegalovirus (CMV) Specific Cytotoxic T Lymphocytes (CTL) When Used for Prophylaxis Against CMV in Recipients of Allogeneic, T Cell Depleted Stem Cell Transplants Phase 1
Completed NCT01986010 - Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults (V160-001) Phase 1
Recruiting NCT03004261 - CMV-CTL for the Treatment of CMV Infection After HSCT Phase 4
Recruiting NCT02600065 - Analysis of CMV Infections in Patients With Brain Tumors or Brain Metastases During and After Radio(Chemo)Therapy N/A
Completed NCT00170170 - Risk Factors for Cytomegalovirus Disease in Solid Organ Transplantation N/A
Completed NCT00000593 - Viral Activation Transfusion Study (VATS) N/A
Recruiting NCT03266640 - Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV) Phase 2
Recruiting NCT03698435 - (Val)Ganciclovir TDM in Transplant Recipients
Completed NCT01594437 - Safety Study of Human Anti-Cytomegalovirus Monoclonal Antibody Phase 1
Completed NCT00372229 - A Study of Valcyte (Valganciclovir) CMV Prophylaxis After Renal Transplantation Phase 3
Completed NCT00353977 - Accelerated Immunization to Induce Cytomegalovirus Immunity in Stem Cell Donors Phase 2